Planet 13 Holdings Past Earnings Performance
Past criteria checks 0/6
Planet 13 Holdings's earnings have been declining at an average annual rate of -44.9%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 19.9% per year.
Key information
-44.9%
Earnings growth rate
-31.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 19.9% |
| Return on equity | -68.4% |
| Net Margin | -74.7% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
The Market Lifts Planet 13 Holdings Inc. (CSE:PLTH) Shares 25% But It Can Do More
May 01
Market Cool On Planet 13 Holdings Inc.'s (CSE:PLTH) Revenues Pushing Shares 26% Lower
Mar 17Revenues Tell The Story For Planet 13 Holdings Inc. (CSE:PLTH)
Jan 06Sentiment Still Eluding Planet 13 Holdings Inc. (CSE:PLTH)
Aug 17Revenue Downgrade: Here's What Analysts Forecast For Planet 13 Holdings Inc. (CSE:PLTH)
Nov 28We Think Shareholders Will Probably Be Generous With Planet 13 Holdings Inc.'s (CSE:PLTH) CEO Compensation
Jul 07Planet 13 Holdings Inc.'s (CSE:PLTH) Has Found A Path To Profitability
May 07The Planet 13 Holdings (CSE:PLTH) Share Price Has Soared 333%, Delighting Many Shareholders
Mar 03The Chief Financial Officer of Planet 13 Holdings Inc. (CSE:PLTH), Dennis Logan, Just Sold 33% Of Their Holding
Jan 09
Are Insiders Selling Planet 13 Holdings Inc. (CSE:PLTH) Stock?
Dec 23Earnings Update: Here's Why Analysts Just Lifted Their Planet 13 Holdings Inc. (CSE:PLTH) Price Target To US$5.56
Nov 27Revenue & Expenses BreakdownBeta
How Planet 13 Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 99 | -74 | 51 | 0 |
| 30 Sep 23 | 100 | -95 | 56 | 0 |
| 30 Jun 23 | 101 | -56 | 55 | 0 |
| 31 Mar 23 | 104 | -53 | 55 | 0 |
| 31 Dec 22 | 105 | -60 | 56 | 0 |
| 30 Sep 22 | 110 | -15 | 58 | 0 |
| 30 Jun 22 | 117 | -12 | 68 | 0 |
| 31 Mar 22 | 121 | -16 | 73 | 0 |
| 31 Dec 21 | 119 | -22 | 69 | 0 |
| 30 Sep 21 | 110 | -34 | 61 | 0 |
| 30 Jun 21 | 100 | -31 | 46 | 0 |
| 31 Mar 21 | 78 | -30 | 34 | 0 |
| 31 Dec 20 | 70 | -25 | 33 | 0 |
| 30 Sep 20 | 67 | -8 | 31 | 0 |
| 30 Jun 20 | 61 | -10 | 32 | 0 |
| 31 Mar 20 | 67 | -7 | 33 | 0 |
| 31 Dec 19 | 64 | -12 | 34 | 0 |
| 30 Sep 19 | 55 | -7 | 29 | 0 |
| 30 Jun 19 | 44 | -6 | 23 | 0 |
| 31 Mar 19 | 31 | -12 | 19 | 0 |
| 31 Dec 18 | 21 | -11 | 14 | 0 |
| 30 Sep 18 | 16 | -9 | 9 | 0 |
| 30 Jun 18 | 14 | -8 | 6 | 0 |
| 31 Mar 18 | 11 | -1 | 4 | 0 |
| 31 Dec 17 | 9 | -1 | 3 | 0 |
| 31 Dec 16 | 2 | -2 | 1 | 0 |
Quality Earnings: PLTH is currently unprofitable.
Growing Profit Margin: PLTH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PLTH is unprofitable, and losses have increased over the past 5 years at a rate of 44.9% per year.
Accelerating Growth: Unable to compare PLTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLTH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: PLTH has a negative Return on Equity (-68.38%), as it is currently unprofitable.